To hear about similar clinical trials, please enter your email below
Trial Title:
A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy
NCT ID:
NCT06101966
Condition:
Cervical Cancer
Radiotherapy
Distant Metastasis
Prognostic Model
Risk Factor
Conditions: Official terms:
Neoplasm Metastasis
Uterine Cervical Neoplasms
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Radiation
Intervention name:
external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)
Description:
Radical RT consisted of external pelvic beam radiotherapy (EBRT) and individualized
high-dose-rate intracavitary brachytherapy (HDR-ICBT).Cisplatin-based concurrent
chemoradiotherapy (CCRT) was recommended for CC patients unless for economic status, age
consideration and patients' desires.
Arm group label:
cervical cancer patients with radiotherapy
Summary:
This study aims to help to screen out appropriate cases for consolidation therapy and
more intensive follow up.
Detailed description:
Some cervical cancer patients experienced distant metastasis quickly after receiving
complete radiotherapy and have a worse prognosis. However, there were few studies focused
on these patients and with early distant metastasis. It is significant to predictive and
screen out cervial cancer patients with a high risk of early metastasis for more
comprehensive treatments and follow-up plans
Criteria for eligibility:
Study pop:
cervical cancer patients recevied definitive radiotherapy.
Sampling method:
Non-Probability Sample
Criteria:
Inclusion Criteria:
- patients confirmed as cervical cancer by biopsies and treated with radiotherapy were
initially enrolled
Exclusion Criteria:
- (1) patients treated with surgery. (2) patient received incomplete treatment
somewhere else. (3) patients with cancer history. (4) patients with pelvic surgery
history. (5) patients without complete pre-treatment medical information. (6)
patients with unfinished radical radiotherapy. (7) patients suffered from metastasis
within 3 months after radiotherapy. (8) patients without complete 1-year follow-up
materials
Gender:
Female
Minimum age:
20 Years
Maximum age:
85 Years
Healthy volunteers:
No
Locations:
Facility:
Name:
Fujian Cancer Hospital
Address:
City:
Fuzhou
Zip:
350014
Country:
China
Start date:
December 1, 2023
Completion date:
December 1, 2027
Lead sponsor:
Agency:
Fujian Cancer Hospital
Agency class:
Other
Source:
Fujian Cancer Hospital
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT06101966
